A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.

• 影响指数: 1.282
• 发表时间: Oct 2019 15
• 来源期刊: Intern Med
• DOI: 10.2169/internalmedicine.2875-19
• PMID: 31292383
• 文章类型: Case Reports
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Watanabe H,Ohashi K,Nishii K,Seike K,Makimoto G,Hotta K,Maeda Y,Kiura K

关键词: EGFR mutations; lung adenocarcinoma; nivolumab; tumor-associated macrophages

Mesh: Adenocarcinoma of Lung / diagnosis drug therapy genetics; Aged; B7-H1 Antigen / metabolism; Biopsy; DNA Mutational Analysis; DNA, Neoplasm / genetics; ErbB Receptors / genetics; Humans; Lung / diagnostic imaging metabolism; Lung Neoplasms / diagnosis drug therapy genetics; Macrophages / pathology; Male; Mutation; Nivolumab / therapeutic use; Tomography, X-Ray Computed

Abstract

Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PD-L1)-negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for more than 2 years. A pathological examination revealed infiltration of CD8-positive lymphocytes and macrophages expressing CD68, CD206, and PD-L1 into the PD-L1-negative tumor; CD206 expression is a marker of immunosuppressive tumor-associated macrophages (TAMs). The presence of PD-L1-positive TAMs in the tumor environment might be a predictor of a positive response to anti-PD-1 antibodies.